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Abstract
Objective and design The aim was to investigate the
signaling mechanisms and regulation of bradykinin (BK)-
induced inﬂammation in rat knee joint.
Materials and methods Knee joints of anesthetized rats
were perfused with BK (0.1–1.0 lM), and synovial plasma
extravasation (PE) was evaluated by spectrophotometrical
measurement of Evans Blue leakage. To examine the sig-
naling pathway, B1 antagonist [des-Arg10]-HOE140 (0.1–
1.0 lM) and B2 antagonist HOE140 (0.05–1.0 lM), cal-
citonin gene-related peptide (CGRP) antagonist CGRP8-37
(0.5–1.0 lM), prostaglandin E2 antagonist AH-6809 (0.1–
1.0 lM), and histamine H1 antagonist mepyramine (0.1–
1.0 lM) were used. Nociceptin (0.0001–1.0 lM) and
antagonist J-113397 were tested for modulation of BK-
induced PE. The analyses were compared side-by-side with
5-hydroxytryptamine-induced PE.
Results BK perfusion dose-dependently induced PE,
which was blocked by HOE140, CGRP8-37, AH-6809, and
mepyramine. It was also inhibited by nociceptin, which
could be reversed by antagonist J-113397. In contrast,
5-hydroxytryptamine-induced PE was biphasically regu-
lated by nociceptin and was not antagonized by CGRP8-37.
Conclusions BK-induced PE is mediated by B2 receptors
and may involve CGRP, prostaglandin, and histamine
pathways. BK-induced PE is inhibited by nociceptin
through the activation of ORL1 receptors. There are dif-
ferences between BK- and 5-hydroxytryptamine-induced
inﬂammation in signaling and modulation.
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Introduction
Inﬂammation as well as its associated pain and plasma
extravasation (PE, the cause of swelling) in the joint—
characteristics of arthritis—can be produced and mediated
by multiple neurobiochemical molecules, such as brady-
kinin (BK), 5-hydroxytryptamine (5-HT), histamine, ATP,
prostaglandins (PGs), and cytokines [1–3]. BK and 5-HT,
the two naturally occurring neurotransmitters, are among
the strongest inﬂammatory mediators released by periphe-
ral nervous terminals, platelets, and mast cells upon
noxious stimulations and synovial tissue injury, causing PE
and pain in the joints [4–6]. Studies suggest that the
mechanisms underlying the BK- and 5-HT-induced PE
have signiﬁcant similarities. Both BK and 5-HT stimulate
PE by activating sympathetic efferent terminals in the
synovia. Selective lesion of the lumbar sympathetic gan-
glia, but not the lesion of the C-ﬁber afferents, substantially
decreases BK- and 5-HT-induced PE [4–6]. Other mecha-
nisms by which BK and 5-HT could act on primary sensory
neurons or other cells to produce PE may also come into
play however. There have been studies to address the
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Some studies have suggested that BK is able to stimulate
the release of the neurotransmitters calcitonin gene-related
peptide (CGRP) and PGs [9, 10]. However, more thorough
investigations are required to address the receptor-signal-
ing mechanisms of BK in inducing inﬂammation in the
joints.
The process of inﬂammation is tightly regulated by
several neurotransmitters. There has been a signiﬁcant
amount of literature reporting the peripheral regulatory
effect of opioids in the knee joints both in animal models
and in human clinical studies [11, 12]. The majority of
these studies have mainly focused on three classical types
(l, d, and j) of opioids and receptors. Recent studies have
revealed that nociceptin (also named orphanin FQ) and its
receptor ORL1 (opioid-receptor-like receptor 1, also
named NOR), considered as the fourth and atypical
member of the endogenous opioid family [13, 14], play a
signiﬁcant role in the modulation of inﬂammation and
nociception [15, 16]. Nociceptin and the ORL1 receptors
are widely distributed throughout the central and peripheral
nervous systems, including sensory and sympathetic gan-
glia [17–19]. Studies have suggested that nociceptin and
ORL1 could mediate opioid-like and anti-opioid effects
[20]. Some studies have shown that nociceptin induces
nociception [13], while others have demonstrated an
inhibitory modulation of pain and inﬂammation [21, 22]. A
study by Grond et al. [23] demonstrated that nociceptin bi-
directionally modulates 5-HT-induced PE in the rat knee
joint, with lower doses of nociceptin potentiating and
higher doses inhibiting the effect of 5-HT. However, the
regulation of BK-induced PE in the knee joint by noci-
ceptin has not been studied.
In the present study, we employed the rat knee-joint
perfusion model, a well-established experimental animal
model for inﬂammation [4–6, 24], to examine the signaling
pathways of BK-induced inﬂammation and its modulation
by nociceptin. We applied selective antagonists to analyze
the receptor pathways and other mediators involved. We
compared the analyses with those of 5-HT-induced PE
under the same experimental conditions.
Materials and methods
Animals
All experiments that employed animals were approved by
the Institutional Animal Care and Use Committee
(IACUC) of the University of California, San Francisco.
Guidelines and policies set by the National Institutes of
Health and the Public Health Service on the care and use of
laboratory animals were followed at all times. Every effort
was made to minimize animal suffering.
Male Sprague-Dawley rats (Bantin and Kingman,
Fremont, CA) weighing 320–350 g were used in the knee-
joint perfusion experiments. Rats were housed individually
in cages at room temperature (approximately 25C) under
controlled lighting conditions (lights on from 6 a.m. to 6
p.m.) with free access to food and water.
Chemicals and reagents
BK, BK receptor B1-selective antagonist [des-Arg10]-
HOE 140, B2-selective antagonist HOE 140, and 5-HT
(Sigma-RBI, St. Louis, MO); 5-HT1A/1B receptor selec-
tive antagonist (-)pindolol, 5-HT2A receptor selective
antagonist ketanserin, CGRP receptor antagonist CGRP
(8-37), and histamine H1 receptor selective antagonist
mepyramine (Tocris Bioscience, Ellisville, MO); prosta-
glandin E2 (and D2) receptor antagonist AH-6809
(Cayman, Ann Arbor, MI); and nociceptin (Bachem,
Torrance, CA), were used in rat knee-joint perfusion. The
ORL1 receptor antagonist J-113397 was generously pro-
vided by Banyu Pharmaceutical (Tsukuba, Ibaraki, Japan).
These chemicals were dissolved in normal saline and were
freshly prepared prior to performing perfusion experi-
ments. Evans Blue dye (Sigma-RBI) was also prepared in
saline at a concentration of 20 mg/ml. All working solu-
tions were used within 12 h after preparation and would
not be stored for re-use.
Intra-articular perfusion and measurement
of PE in the rat knee joint
The rat knee-joint perfusion and PE measurement were
performed as previously described [6]. Brieﬂy, rats were
anesthetized with intraperitoneal injection of sodium pen-
tobarbital (65 mg/kg body weight) (Abbott, Chicago, IL),
and then Evans Blue dye (50 mg 2.5 ml
-1 kg
-1 body
weight) was injected into the tail vein as an indicator for PE.
The skin overlying the knee was excised to expose the joint
capsule, and a 30-gauge, 1.25-cm-long needle was inserted
into the knee joint for infusion of solution. After infusion of
about 100 ll of saline, a 25-gauge needle was placed into
the joint space for outﬂow of solution, with the tips of the
two needles separated approximately 3 mm apart. The rates
of both infusion and outﬂow were controlled at 200 ll/min
by a push–pull syringe pump (SP120p, WPI, Sarasota, FL).
The perfusion outﬂow was continuously collected in
microcentrifuge tubes at 1 ml/tube every 5 min for a total of
14 tubes (70 min). The samples were immediately centri-
fuged to remove any red blood cells if present; only blood-
free samples were used to measure the optical density (OD,
proportional to the concentration of Evans Blue dye) at
874 K. Moriyama et al.620 nm on a spectrometer Spectronic 21D (Spectronic
Instruments, Rochester, NY) [25]. Rat knees that had evi-
dence of physical damage, swelling, or improperly aligned
inﬂow and outﬂow needles were excluded from the study.
The number of rat knees that were successfully perfused in
each group was C6 or as indicated in the ﬁgures. The
baseline value of PE was determined by averaging OD620
measurements of three continuous perfusion samples with
0.9% saline in the ﬁrst 15 min. Another 10-min period was
given for the application of antagonists or modulators prior
to the perfusion of the primary PE inducer (BK or 5-HT).
Perfusion of saline for the entire 70-min period was per-
formed as a control.
To assess the dose–response of BK-induced PE, ﬁve
concentrations of BK (0.1–1.0 lM) were perfused for
45 min after the 25-min saline infusion [3]. For 5-HT-
induced PE, a concentration of 1 lM of 5-HT was chosen
based on our own previous studies [6, 23]. To examine the
modulatory effect of nociceptin on BK- or 5-HT-induced
PE, various concentrations of nociceptin (0.0001–1.0 lM)
were perfused 10 min before the perfusion of BK or 5-HT.
To evaluate whether the effects of BK, 5-HT, and noci-
ceptin observed in this study were speciﬁcally receptor-
mediated, and whether other mediators were involved,
selective antagonists for the respective receptors and
receptorsubtypeswereused10 minbeforetheapplicationof
BK, 5-HT, or nociceptin. Dosages of the antagonists—[des-
Arg10]-HOE 140 (0.5–1.0 lM), HOE 140 (0.05–1.0 lM),
(-)pindolol (0.5–1.0 lM), ketanserin (0.1–1.0 lM),
CGRP8-37 (0.5–1.0 lM), AH-6809 (0.1–1.0 lM), mepyr-
amine (0.1–1.0 lM), and J-113397 (0.005, 1.0 lM)—were
chosen based on their binding afﬁnities for respective
receptors and in vivo doses reported in the literature [7, 23,
26–32], and with additional consideration of possible
degradation during perfusion.
Statistical analysis
Data are presented as mean ± standard error of the mean
(SEM) for the complete curves of dose–response and time–
course measurements, as well as for measurements of the
area under the curve (AUC) from 30 to 70 min. Statistical
differences between two groups were analyzed by a
Student’s t-test, and those between different groups and
doseswereanalyzedbyANOVAwithFisher’spost-hoctest.
Results
Dose response and time course of BK-induced PE
Intra-articular perfusion of BK produced signiﬁcant PE in
the rat knee joints in a dose-dependent manner, with
0.1 lM BK inducing small but signiﬁcant PE as compared
with saline (P\0.05) and 0.25 lM BK doubling it
(P\0.01). At a concentration of 0.5 lM, BK induced a
PE that was threefold that of 0.1 lMB K( P\0.001)
(Fig. 1a). As a negative control, perfusion with saline alone
did not produce PE in the knee joints. At a concentration of
1 lM, BK induced the maximum PE. The ED50 for BK in
stimulating PE was estimated to be 0.32 lM (Fig. 1b). The
signiﬁcant increase in PE occurred after 10 min of BK
perfusion (35 min in the time scale in Fig. 1a), reached a
peak level after 20 min of BK perfusion, and declined
slightly over time. The effect of 0.5 lM of BK was com-
parable to that of 1 lM of 5-HT. The concentrations of
0.5 lM of BK and 1 lM of 5-HT were chosen in the
subsequent experiments for analyzing their signaling and
modulation mechanisms in inducing PE in the rat knee
joints.
Speciﬁc receptor mediation of BK- and
5-HT-induced PE
To examine which subtypes of receptors mediate BK- and
5-HT-induced PE, receptor subtype-selective antagonists
were perfused 10 min before the perfusion of BK and
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Fig. 1 BK-induced PE in the rat knee joint. a The dose response and
time course of BK-induced PE. The starting points of perfusion of BK
or saline are indicated. b The dose-dependent effect and the
estimation of ED50 of BK in producing PE in the rat knee joint,
calculated as the area under the curve (AUC, OD 620 nm) between
the time points of 30 and 70 min. The number of rat knee joints
perfused in each group was n C 6. Data are presented as the
mean ± SEM
BK-induced plasma extravasation in rat knee joint 8755-HT, respectively. The BK receptor B1-selective antago-
nist [des-Arg10]-HOE 140 (0.5–1 lM) did not show any
blocking effect on BK-induced PE. B2-selective antagonist
HOE 140, at concentrations of 0.05–0.5 lM, displayed a
dose-dependent blockade effect (Fig. 2a); response of
1.0 lM of HOE140 was equal to that of 0.5 lM (Fig. 3a).
There are seven types of 5-HT receptors, some of them
even have subtypes. As a more complete investigation was
conducted in our previous study using the same experi-
mental model [6], the present study only used two
antagonists to demonstrate the receptor mediation. In
5-HT-induced PE, the 5-HT1A/1B antagonist (-)pindolol
at 0.5 and 1 lM concentrations showed very little antag-
onizing effect; however, the 5-HT2A antagonist ketanserin
signiﬁcantly blocked PE in a dose-dependent manner
(Fig. 2b). These results indicate that the observed PE
produced by either BK or 5-HT is mediated by speciﬁc
subtype(s) of receptors.
Involvement of CGRP, prostaglandins, and histamine
in BK- and 5-HT-induced PE
To investigate whether other known inﬂammation media-
tors and neurotransmitters are involved in the signaling
pathways of BK- or 5-HT-induced PE, we applied speciﬁc
antagonists of the CGRP, PGE2, and histamine H1 recep-
tors. These receptors have been shown to be involved in
inﬂammation [7, 33, 34]. CGRP receptor antagonist
CGRP8-37, PGE2 receptor antagonist AH-6809, and
histamine H1 receptor antagonist mepyramine each par-
tially inhibited BK-induced PE in a dose-dependent
manner; when applied together, they were able to reduce
BK-induced PE to the extent near (but not C) that of BK
B2-selective antagonist HOE140 alone. When all four
antagonists (i.e., CGRP8-37, AH-6809, mepyramine, and
HOE140) were co-perfused, they markedly inhibited the
BK-induced PE, which exceeded the blocking effect of
HOE140 alone (Fig. 3a). In contrast, in 5-HT-induced PE,
only AH-6809 and mepyramine showed a partial inhibi-
tory effect, whereas CGRP8-37 had no effect (Fig. 3b).
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Fig. 3 The involvement of
CGRP, PGE2, and histamine in
BK and 5-HT-induced PE. The
individual or the combination of
the antagonists was applied
10 min prior to the perfusion of
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876 K. Moriyama et al.The results suggest that CGRP, PGs, and histamine are
all involved in the signaling of BK-induced PE; and
that PGs and histamine, but not CGRP, are involved in
5-HT-induced PE.
Effect of nociceptin on BK- and 5-HT-induced PE
To examine the effect of nociceptin on BK- and 5-HT-
induced PE, we perfused nociceptin without or with the
ORL1 receptor antagonist J-113397 prior to the application
of the primary PE inducer BK or 5-HT. At subnanomolar
concentrations (\10
-3 lM), nociceptin had very little
effect on BK-induced PE. With an increase in concentra-
tion (C10
-3 lM), nociceptin inhibited BK-induced PE
dose-dependently, with 0.01 lM of nociceptin showing an
inhibition by approximately 32% (AUC, 0.82 ± 0.2,
P[0.05), 0.1 lM by 44% (AUC, 0.67 ± 0.18, P\0.05),
and 1 lM by 51% (AUC, 0.58 ± 0.07, P\0.01). Noci-
ceptin did not facilitate BK-produced PE at any
concentration. The inhibitory effect of nociceptin on BK-
produced PE was effectively blocked by 1 lM of antago-
nist J-113397, indicating that it was speciﬁcally mediated
by ORL1 receptors (Fig. 4a, b). Nociceptin or J-113397
alone did not produce PE in the rat knee joints (data not
shown).
The effect of nociceptin on 5-HT-induced PE was dose-
related and bi-directional. Lower concentrations of noci-
ceptin (10
-4 and 10
-3 lM) potentiated 5-HT-induced PE
by 45 and 50% (AUC, 1.50 ± 0.17 and 1.55 ± 0.12,
P\0.05), respectively. Higher concentrations of noci-
ceptin (0.1 and 1 lM) inhibited 5-HT-induced PE. At a
concentration of 1 lM, nociceptin inhibited 5-HT-induced
PE by 45% (AUC, 0.57 ± 0.14, P\0.05). At a concen-
tration of 0.01 lM, nociceptin showed neither potentiation
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Fig. 4 The effect of nociceptin on BK- and 5-HT-induced PE. a The
dose-dependent effect of nociceptin on BK-induced PE and its
reversal by ORL1-antagonist J-113397, as presented by time course
curves. The starting time points of perfusion of different agents are
indicated. b and c The comparison of dose-response of nociceptin and
its antagonist J-113397 on BK- and 5-HT-induced PE, presented as
AUC (OD 620 nm) between time points of 30 and 70 min. Two
concentrations (0.005 and 1 lM) of J-113397 were used to block the
effect of low and high concentrations of nociceptin, respectively. Data
are presented as the mean ± SEM (n C 6). *P\0.05, **P\0.01,
as compared with the control group (BK or 5-HT alone)
BK-induced plasma extravasation in rat knee joint 877nor inhibition. Antagonist J-113397 blocked both potenti-
ation and inhibition effects produced by low and high
concentrations of nociceptin on 5-HT-produced PE,
respectively, indicating that both effects were speciﬁcally
mediated by ORL1 receptors (Fig. 4b).
Discussion
BK and 5-HT are two of the most potent stimulants and
mediators of inﬂammation in the joints. Therefore, it is
important to understand the processes and pathways in BK-
and 5-HT-induced inﬂammation. Previous studies showed
that both BK and 5-HT produce PE through an activation
of sympathetic nerve terminals [4–6].
The present study has investigated the signaling mech-
anism of BK-induced PE and its modulation using the rat
knee-joint perfusion model, and compared them with those
of 5-HT-induced PE. Our experiments clearly demonstrate
that BK-induced PE in the rat knee is dose-dependent, and
is speciﬁcally mediated by B2 subtype receptors, but not by
B1, as indicated by antagonist blockade results. These
results are in agreement with previous reports using similar
animal models [3, 35, 36]. Early studies showed that B2
receptors are expressed in human synovial tissues [37] and
that BK can be released from peripheral nerve terminals, as
well as from peripheral tissues and cells including endo-
thelial cells and neutrophils, upon nociceptive stimulation
[37–40]. These ﬁndings indicate an important role of BK
and B2 receptors in knee-joint inﬂammation. However, our
study could not rule out the contribution of the B1 subtype
receptors. One reason is the conditions and timing of the
B1 receptor expression. While B2 receptors are normally
expressed in many tissues, the B1 receptors have little or
very low expression under normal conditions. The
expression of B1 could, however, be upregulated over a
period of hours following a chronic exposure to noxious
stimuli or inﬂammation factors [41]. Our experimental
knee perfusion model was designed to analyze acute
inﬂammation events within 1 h. Previous studies have
reported that B1 receptors can be induced and activated in
chronic inﬂammation [36]. Another possible reason is that
our present study only used BK in its full-length peptide
form, which is selective for the B2 receptors and much less
selective for the B1 [41]. Without using a B1-selective
agonist to induce PE, any assessment of the contribution of
B1 receptors would be inconclusive.
Our study also conﬁrms that 5-HT induces PE via spe-
ciﬁc 5-HT2A subtype of serotonin receptor, which is
consistent with previous studies [6].
Using speciﬁc receptor antagonists, the study demon-
strates that other inﬂammation mediators and neuro-
transmitters are involved in the processes of BK- and
5-HT-induced PE. Results show that CGRP, PGs, and
histamine are involved in the signaling pathway of
BK-induced PE. As the blocking effects of each or the
combination of the three antagonists (CGRP8-37, AH-6809,
and mepyramine) are smaller than the effects of the B2
antagonist HOE 140, CGRP, PG, and histamine are likely
to be activated downstream of the activation of B2 recep-
tors. Our results also suggest that these mediators can in
turn augment the BK effect, as the three antagonists and B2
antagonist together dramatically blocked BK-induced PE,
an effect signiﬁcantly greater than that of B2 antagonist
alone. There is evidence that BK is able to induce the
release of CGRP, PGs, and histamine in a variety of tissues
and cells [9, 10, 42], and these secondary mediators in turn
can cause or enhance inﬂammation [7, 43–45]. In com-
parison, our results show that in 5-HT-stimulated PE, PGs
and histamine also play important roles, which is in
agreement with our previous studies [7, 46], but CGRP is
apparently not involved.
A previous study by Cambridge and Brain investigated
the signaling mechanisms of BK-induced PE in a similar
knee-joint perfusion model [35]. There are agreements and
differences between their ﬁndings and ours. One important
difference is whether secondary mediators, such as neuro-
peptides and histamine, are involved in BK-induced PE.
Their results suggested no secondary release of inﬂam-
mation mediators is involved. One possible explanation is
an obvious difference in the perfusion scheme in the two
studies. The study by Cambridge and Brain perfused test-
ing agents for 5 min and analyzed a single sample of 1 ml
collected 10 min after, whereas our study carried out
continuous perfusion for 45 min and collected samples
every 5 min for the whole length of time. Therefore, our
present study might be able to obtain results different from
those of the early study.
The present study demonstrated that BK- and 5-HT-
induced PE are differentially regulated by nociceptin. Our
data show that the modulation by nociceptin of 5-HT-
stimulated PE is bi-phased: lower concentrations of noci-
ceptin potentiate and higher concentrations inhibit the PE.
In contrast, the modulation by nociceptin of BK-stimulated
PE is mono-phased: only a dose-dependent inhibition
exists. One possible explanation is that there might be a
signiﬁcant difference in nociceptin regulation of the BK
and 5-HT signaling systems, including the regulation of
presynaptic and post-synaptic events. Nociceptin may dif-
ferentially regulate the release of 5-HT and BK. It has been
reported that nociceptin bi-directionally regulates the
release of 5-HT in neurons [47]. Secondly, nociceptin may
differentially regulate the second mediators downstream of
BK or 5-HT receptor activation. For example, nociceptin
can inhibit the release of CGRP [15, 48]; the latter
is an important mediator in BK-induced PE, but not in
878 K. Moriyama et al.5-HT-inducedPE,asdemonstratedbythisstudy.Inaddition,
it is known that while BK is degraded by peptidases after
action, the effect of 5-HT can be reduced and terminated by
pre-synaptic serotonin transporters, which re-uptake and
remove 5-HT from the synaptic clefts. A previous study
reported that nociceptin at micromolar concentrations
inhibits dopamine and GABA transporters and has little
effect on serotonin transporters [49]. The effect of lower
concentrations(nanomolarandsubnanomolar)ofnociceptin
was not examined however. There is a possibility that
nociceptin may have a dose-dependent effect on serotonin
transporters and thus differentially regulates the quantity of
5-HT available for activating post-synaptic serotonin
receptors in the knee joints.
In summary, BK- and 5-HT-induced PE in the rat knee
joints are mediated by their speciﬁc receptors and down-
stream inﬂammation mediators. There are ﬁne differences
between BK- and 5-HT-induced PE in their signaling
pathways and their regulation by nociceptin. The under-
standing of these mechanisms could help to develop new
therapies for acute and chronic inﬂammation in the joints.
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